40 completed, 8 terminated, 4 unknown, 4 withdrawn. 58 Phase 2, 7 Phase 1, 5 Phase 3.
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo - Heart Failure, Overactive Bladder | Phase 2 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2024-06-15 | 2026-03-12 |
| A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB) Mirabegron 50 MG, Oxybutynin Chloride 5 MG - Overactive Bladder | Phase 2 | Unknown | Seoul National University Hospital | 44 | 2024-04-01 | 2024-03-08 |
| Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms OnabotulinumtoxinA - Urinary Incontinence, Overactive Bladder Syndrome | Phase 2 / Phase 3 | Active not recruiting | Northwestern University | 66 | 2023-07-13 | 2026-10-13 |
| Reduced-dose Botox for Urgency Incontinence Among Elder Females Botox 50 Unit Injection, Botox 100 Unit Injection - Overactive Bladder, Urinary Incontinence in Old Age | Phase 1 / Phase 2 | Active not recruiting | Dartmouth-Hitchcock Medical Center | 376 | 2023-05-12 | 2026-02-03 |
| Lidocaine Patches Prior to Percutaneous Nerve Evaluation Lidocaine patch, Placebo - Overactive Bladder, Urge Incontinence | Phase 2 | Completed | University of Louisville | 39 | 2023-05-01 | 2025-02-03 |
| Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks 500 mg NDS-446 - Overactive Bladder | Phase 2 | Completed | Loyola University | 53 | 2023-01-01 | 2026-06-17 |
| Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children Beta3-Agonists, Adrenergic, Anticholinergic drug, Solifenacin - Voiding Disorders, Overactive Bladder | Phase 1 / Phase 2 | Unknown | Mansoura University | 70 | 2022-02-01 | 2022-02-15 |
| Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) Placebo, BAY1817080 - Overactive Bladder | Phase 2 | Completed | Bayer | 99 | 2020-09-16 | 2022-12-22 |
| NOGO for an Overactive Bladder extract from Angelica archangelica leaf, Placebo - Overactive Bladder, Nocturia | Phase 2 | Unknown | SagaNatura | 200 | 2020-05-01 | 2020-11-12 |
| A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 2 | Completed | Dong-A ST Co., Ltd. | 306 | 2018-07-10 | 2020-02-07 |
| A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo - Overactive Bladder | Phase 2 | Completed | Velicept Therapeutics, Inc. | 1413 | 2018-07-09 | 2020-03-02 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo - Overactive Bladder | Phase 2 | Completed | Velicept Therapeutics, Inc. | 438 | 2018-02-19 | 2020-03-02 |
| Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. TAC-302, Placebo - Detrusor Underactivity, Overactive Bladder | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 195 | 2017-09-09 | 2025-01-20 |
| Mirabegron For Erectile Dysfunction Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2017-08-01 | 2021-01-05 |
| Study of ONO-8577 in Patients With Overactive Bladder ONO-8577, solifenacin succinate + mirabegron, Placebo - Overactive Bladder | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 207 | 2017-04-07 | 2024-05-03 |
| Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Withdrawn | UroGen Pharma Ltd. | 2016-10-01 | 2017-06-16 | |
| A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment fesoterodine 4mg, Oxybutynin, placebo - Overactive Bladder, Mild Cognitive Impairment | Phase 2 | Completed | University of Alberta | 47 | 2016-08-01 | 2020-02-19 |
| Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms Sports TENS 2 - Overactive Bladder | Phase 2 | Withdrawn | Meir Medical Center | 2016-03-01 | 2016-03-16 | |
| Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB) onabotulinum toxin A - Overactive Bladder | Phase 2 | Completed | The Hospital of Vestfold | 14 | 2016-03-01 | 2018-11-26 |
| Cystoscopic Ablation Via RF Energy Clinical Trial Amphora OAB Device - Overactive Bladder | Phase 1 / Phase 2 | Terminated | Amphora Medical, Inc. | 63 | 2015-02-01 | 2019-05-07 |
Showing 20 of 58. Sign in to see all of them.
Urinary Bladder, Overactive (58) · Urinary Incontinence (13) · Urinary Incontinence, Urge (6) · Lower Urinary Tract Symptoms (2) · Spinal Cord Injuries (2) · Cognitive Dysfunction (1) · Erectile Dysfunction (1) · Fecal Incontinence (1) · Heart Failure (1) · Male Urogenital Diseases (1) · Multiple Sclerosis (1) · Nocturia (1) · Urinary Bladder, Underactive (1) · Urinary Tract Infections (1) · Urologic Diseases (1)
Female Urogenital Diseases (58) · Female Urogenital Diseases and Pregnancy Complications (58) · Pathological Conditions, Signs and Symptoms (58) · Signs and Symptoms (58) · Urinary Bladder Diseases (58) · Urogenital Diseases (58) · Urological Manifestations (58) · Male Urogenital Diseases (57) · Urologic Diseases (57) · Lower Urinary Tract Symptoms (56) · Urination Disorders (18) · Urinary Incontinence (5) · Nervous System Diseases (3) · Central Nervous System Diseases (2) · Mental Disorders (2)
Botulinum Toxins, Type A (11) · Tolterodine Tartrate (7) · Solifenacin Succinate (4) · fesoterodine (3) · mirabegron (3) · abobotulinumtoxinA (2) · casopitant (2) · incobotulinumtoxinA (2) · oxybutynin (2) · solabegron (2) · Adrenergic beta-3 Receptor Agonists (1) · Cholinergic Antagonists (1) · DA-8010 (1) · Dimethyl Sulfoxide (1) · Drug Therapy (1)
Pfizer (4) · GlaxoSmithKline (3) · Ono Pharmaceutical Co., Ltd. (3) · Allergan (2) · Bayer (2) · Buddhist Tzu Chi General Hospital (2) · Loyola University (2) · Sanofi (2) · University of Zurich (2) · UroGen Pharma Ltd. (2) · Velicept Therapeutics, Inc. (2) · APOGEPHA Arzneimittel GmbH (1) · American Oriental Bioengineering, Inc. (1) · Amphora Medical, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (24) · Germany (9) · Czechia (7) · France (7) · Poland (7) · Canada (6) · Netherlands (6) · Belgium (5) · South Korea (5) · Spain (5) · Sweden (5) · United Kingdom (5) · Israel (4) · Taiwan (4) · Hungary (3)
Hann-Chorng Kuo, M.D. (2) · Adrian S Wagg, MD (1) · Alan J Wolffe, PhD (1) · Alvin Chandra, MD (1) · Ami Sidi, Prof MD (1) · Amy Krambeck, MD (1) · Angelo E Gousse, MD (1) · Anne C Cooper, MD, MA (1) · Arthur L Burnett, M.D., M.B.A. (1)
PMID 23218404, PMID 26423260, PMID 12559262, PMID 12811491, PMID 16460875, PMID 17049716, PMID 18584946, PMID 19648387, PMID 19941278, PMID 20384395, PMID 20639026, PMID 20674149, PMID 20804630, PMID 22036776, PMID 22047020, PMID 22174279, PMID 22258963, PMID 22278835, PMID 22464310, PMID 22748867, PMID 23076891, PMID 23741373, PMID 24371246, PMID 24515544, PMID 25006228, PMID 25623739, PMID 26049866, PMID 26210757, PMID 26824901, PMID 26962083, PMID 27214047, PMID 28196724, PMID 28486927, PMID 31233095, PMID 31930360, PMID 32317321, PMID 32791124, PMID 32945735, PMID 34036621, PMID 34978027, PMID 34988092, PMID 36205739, PMID 36892754, PMID 37160401, PMID 37811598, PMID 38402104, PMID 40013530, PMID 41368330
2019 (1)